GRPH Stock Price, Graphite Bio, Inc. Quote, Chart

Market Summary

USD16.32-0.03

Market Closed

-0.18%

GRPH Stock Price

View Fullscreen

GRPH RSI Chart

GRPH Valuation

Market Cap

416.7M

Price/Earnings (Trailing)

-6.65

EV/EBITDA

-3.06

Price/Free Cashflow

-6.63

MarketCap/EBT

-5.94

GRPH Price/Earnings (Trailing)

GRPH Profitability

Return on Equity

-31.63%

Return on Assets

-28.84%

Free Cashflow Yield

-15.09%

GRPH Fundamentals

GRPH Earnings

Earnings (TTM)

-62.7M

Earnings Growth (Yr)

30.44%

Earnings Growth (Qtr)

-152.41%

Breaking Down GRPH Revenue

Last 7 days

3.9%

Last 30 days

-7.7%

Last 90 days

-23.3%

Trailing 12 Months

-18.5%

How does GRPH drawdown profile look like?

GRPH Financial Health

Current Ratio

11.47

GRPH Investor Care

Shares Dilution (1Y)

207.63%

Diluted EPS (TTM)

-7.74

Tracking the Latest Insider Buys and Sells of Graphite Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2022	samsara biocapital, l.p.	bought	1,428,000	4.08	350,000	-
Apr 11, 2022	gutry phil	bought	20,050	4.01	5,000	chief business officer
Apr 11, 2022	samsara biocapital, l.p.	bought	303,068	4.07	74,464	-
Jan 24, 2022	samsara biocapital, l.p.	bought	200,100	8.7	23,000	-
Jan 21, 2022	samsara biocapital, l.p.	bought	899,000	8.99	100,000	-
Jan 20, 2022	samsara biocapital, l.p.	bought	384,497	8.92	43,105	-
Jan 19, 2022	samsara biocapital, l.p.	bought	504,181	9.24	54,565	-
Dec 15, 2021	samsara biocapital, l.p.	bought	227,533	10.19	22,329	-
Nov 22, 2021	samsara biocapital, l.p.	bought	2,047,100	10.15	201,685	-
Oct 15, 2021	samsara biocapital, l.p.	bought	28,727	12.49	2,300	-

Which funds bought or sold GRPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-84,341	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	sold off	-100	-12,086	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-343,398	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-20,000	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-74,770	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-1,537,220	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-1,138,300	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-536,520	-	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-487,446	-	-%
May 15, 2024	HSBC HOLDINGS PLC	sold off	-100	-57,739	-	-%

Are Funds Buying or Selling GRPH?

Are funds buying GRPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GRPH

No. of Funds

Unveiling Graphite Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	ecor1 capital, llc	4.8%	1,219,774	SC 13G/A
Mar 28, 2024	ra capital management, l.p.	16.6%	4,250,856	SC 13D
Mar 28, 2024	alpha wave ventures gp, ltd	14.1%	3,612,211	SC 13G
Mar 25, 2024	point72 asset management, l.p.	3.4%	864,942	SC 13G
Mar 25, 2024	versant venture capital vi, l.p.	8.2%	2,101,199	SC 13D/A
Mar 25, 2024	samsara biocapital, l.p.	4.7%	1,208,473	SC 13G/A
Feb 05, 2024	tang capital partners lp	5.4%	3,117,843	SC 13G
Feb 05, 2024	porteus matthew	6.1%	3,548,529	SC 13G/A
Nov 17, 2023	versant venture capital vi, l.p.	25.4%	14,708,398	SC 13D/A
Feb 14, 2023	samsara biocapital, l.p.	14.5%	8,459,314	SC 13G/A

Recent SEC filings of Graphite Bio, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 09, 2024	424B3	Prospectus Filed
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 11, 2024	424B3	Prospectus Filed
Apr 10, 2024	EFFECT	EFFECT
Apr 09, 2024	S-1/A	Initial Public Offering
Apr 08, 2024	CORRESP	CORRESP
Apr 08, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Graphite Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Graphite Bio, Inc. News

Latest updates

Graphite Bio, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	208.8%	217	70.00	266	287	310	47.00	335	354	379	402	416	387	-
Current Assets	222.2%	217	67.00	239	251	270	47.00	298	327	344	382	401	385	21.00
Cash Equivalents	470.5%	200	35.00	183	129	70.00	44.00	56.00	75.00	185	18.00	395	382	20.00
Net PPE	-9.3%	0.00	0.00	13.00	18.00	33.00	0.00	13.00	10.00	9.00	7.00	6.00	2.00	1.00
Liabilities	-2.8%	19.00	20.00	62.00	63.00	34.00	11.00	18.00	15.00	17.00	18.00	16.00	8.00	32.00
Current Liabilities	2.0%	19.00	19.00	13.00	12.00	14.00	9.00	14.00	12.00	13.00	12.00	11.00	8.00	32.00
Shareholder's Equity	7.9%	198	184	204	224	276	296	316	338	361	384	400	379	-
Retained Earnings	-17.5%	-111	-95.20	-344	-321	-266	-25.28	-217	-193	-167	-141	-122	-107	-70.59
Additional Paid-In Capital	12218.7%	310	3.00	548	546	543	1.00	536	533	529	525	523	487	5.00
Shares Outstanding	161.8%	26.00	10.00	8.00	8.00	8.00	10.00	8.00	8.00	8.00	8.00	3.00	1.00	-
Float	-	-	-	-	151	-	66.00	-	150	-	-	-	817	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-47.3%	-23,937	-16,250	-9,401	-13,655	-21,074	61,460	-22,217	-22,094	-21,240	-15,593	-15,415	-13,784	-8,060	-	-	-
Share Based Compensation	113.7%	947	-6,926	2,161	2,845	3,263	-9,191	3,210	3,360	3,342	2,446	2,374	2,018	1,033	-	-	-
Cashflow From Investing	108.6%	18,000	-208,885	63,875	72,226	43,163	255,350	3,496	-88,217	-170,666	-981	-3,636	-763	-360	-	-	-
Cashflow From Financing	112.6%	171,268	80,576	8.00	124	-8.00	29,909	-59.00	412	-	313	31,890	219,497	165,767	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GRPH Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Operating expenses:

Research and development

$ 10,537

$ 10,325

Selling, general and administrative

5,551

2,291

Total operating expenses

16,088

12,616

Loss from operations

(16,088)

(12,616)

Other income (expense):

Other expense

(1,348)

(54)

Interest income

788

0

Total other income (expense), net

(560)

(54)

Net loss

(16,648)

(12,670)

Other comprehensive loss:

Unrealized loss on marketable securities

(7)

0

Comprehensive loss

$ (16,655)

$ (12,670)

Net loss per share attributable to common stockholders-basic

$ (3.53)

$ (6.50)

Net loss per share attributable to common stockholders-diluted

$ (3.53)

$ (6.50)

Weighted-average Class A common shares outstanding, basic (in shares)

^[1]

4,717,613

1,950,653

Weighted-average Class A common shares outstanding, diluted (in shares)

^[1]

4,717,613

1,950,653

[1]	Retroactively recast for the reverse recapitalization as described in Note 3. See Note 2 for further information on weighted-average common shares outstanding.

GRPH Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 200,357

$ 35,140

Marketable securities

12,922

30,654

Prepaid expenses and other current assets

3,281

1,450

Restricted cash

114

0

Total current assets

216,674

67,244

Property and equipment, net

49

54

Operating lease right-of-use asset

578

318

Deferred offering costs

0

2,739

Security deposit

21

Total assets

217,322

70,376

Current liabilities:

Accounts payable

7,131

5,711

Accrued liabilities

11,757

12,803

Total current liabilities

18,888

18,514

Operating lease liability, net

156

192

Other noncurrent liabilities

111

121

Preferred stock warrants liability

0

871

Total liabilities

19,155

19,698

Commitments and contingencies (Note 6)

Convertible preferred and common stock:

Total convertible preferred and common stock

0

143,390

Stockholders' deficit:

Common stock, par value of $0.001 per share; 79,218,247 Class A shares authorized, and 9,915,013 shares issued at December 31, 2022 and 2023, respectively, and 9,629,171 and 9,739,818 shares outstanding at December 31, 2022 and 2023, respectively

^[1]

0

10

Additional paid-in capital

^[1]

310,061

2,517

Accumulated deficit

^[1]

(111,893)

(95,245)

Accumulated other comprehensive income (loss)

^[1]

(1)

6

Total stockholders’ equity (deficit)

198,167

(92,712)

^[2]

Total liabilities, convertible preferred and common stock and stockholders’ equity (deficit)

217,322

70,376

Series A Convertible Preferred Stock

Convertible preferred and common stock:

Total convertible preferred and common stock

0

44,621

^[2]

Series A-1 Convertible Preferred Stock

Convertible preferred and common stock:

Total convertible preferred and common stock

0

9,893

^[2]

Series B Convertible Preferred Stock

Convertible preferred and common stock:

Total convertible preferred and common stock

0

82,976

Class B Convertible Common Stock

Convertible preferred and common stock:

Total convertible preferred and common stock

$ 0

$ 5,900

^[2]

[1]	Retroactively recast for the reverse recapitalization as described in Note 3.
[2]	Retroactively recast for the reverse recapitalization as described in Note 3.

About Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Ms. Kimberlee Cobleigh Drapkin CPA, CPA
WEBSITE	https://graphitebio.com
INDUSTRY	Biotechnology
EMPLOYEES	120

Graphite Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Graphite Bio, Inc.? What does GRPH stand for in stocks?

GRPH is the stock ticker symbol of Graphite Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Graphite Bio, Inc. (GRPH)?

As of Fri May 17 2024, market cap of Graphite Bio, Inc. is 416.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRPH stock?

You can check GRPH's fair value in chart for subscribers.

What is the fair value of GRPH stock?

You can check GRPH's fair value in chart for subscribers. The fair value of Graphite Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Graphite Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GRPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Graphite Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether GRPH is over valued or under valued. Whether Graphite Bio, Inc. is cheap or expensive depends on the assumptions which impact Graphite Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRPH.